Inovio up 20% on positive INO-5401 data

Inovio Pharmaceuticals (INO +19.7%) is up out the gate in response to positive preliminary results from a Phase 2 clinical trial evaluating T-cell-activating immunotherapy INO-5401, combined with Regeneron and Sanofi’s Libtayo (cemiplimab-rwlc), in newly diagnosed patients with glioblastoma multiforme (GBM). The data will be presented later this week at the SITC Annual Meeting in National Harbor, MD.

At month 6, 80% (n=16/20) of MGMT gene promoter methylated patients and 75% (n=24/32) of unmethylated patients were progression-free, substantially exceeding historial standard-of-care data.

Month 12 and 18 results will be reported next year.

https://seekingalpha.com/news/3514451-inovio-20-percent-positive-inominus-5401-data